Symeres Weert receives new GMP certificate
This week, our facility in Weert NL received a new certificate of GMP compliance from the Dutch authorities.
A decade of integrated drug discovery at Symeres
Symeres celebrates a decade of integrated drug discovery. Our team has been working hard to provide our clients with the best possible solutions for their needs.
Symeres welcomes Karen Damian to the team
We introduce you to our newest Director of Business Development. Karen Damian has a history in the drug development life sciences business.
π-Facial selectivity in the Diels–Alder reaction of glucosamine-based chiral furans and maleimides
Symeres explorations into opportunities to access novel chemical space by using carbohydrates as sustainable chiral starting materials for library synthesis has led to yet another publication.
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same (Organix)
Number: US 2023/0056273 A1
Triazole derivatives and their use as tankyrase inhibitors
Number: WO 2022/008896 A1
Conjugate of saponin, oligonucleotide and galnac
Number: WO 2022/055351 A1
Specific N-terminal attachment of TMTHSI linkers to native peptides and proteins for strain-promoted azide alkyne cycloaddition
Article: Chem. Commun., 2023, Advance Article
Contemporary Chiral Resolutions
Article: Chim. Oggi., 2023, 41 (2)
Comparative biochemical kinase activity analysis identifies rivoceranibas a highly selective VEGFR2 inhibitor (Oncolines)
Article: Cancer Chemother Pharmacol., 2023 (6), 491-499
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.